Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 8, 2017

View Archived Issues

FDA clears IND for phase II study of 177Lu-PSMA-617

Lupin identifies new PARP-1 inhibitors

Ono Pharmaceutical recaps milestones of third quarter of fiscal 2016

Clinical improvement in ADHD seen with fasoracetam in phase I trial, phase II/III study underway

AstraZeneca reviews milestones of fourth quarter 2016

Phase II trial results of RG-7667 for CMV infection prevention in kidney transplant recipients

HIF1-alpha identified as a target for relapsing triple-negative breast cancer

Longevity Biotech and UNMC awarded continuing grant for the development of LBT-3627

GW Pharmaceuticals reports topline results from phase II study of THC:CBD in glioblastoma

Nanjing Hairong, Nanjing Heron patent loxoprofen derivatives

FDA approves Parsabiv to treat secondary hyperparathyroidism in patients on hemodialysis

Amgen reflects on achievements of fourth quarter 2016

Sunshine Lake Pharma discloses 5-HT reuptake inhibitors/5-HT1A receptor agonists

Targeting zinc finger protein SNAI1 induces apoptosis in bladder cancer cells

Vyome Biosciences announces promising results for VB-1953

Marina Biotech signs licensing agreement for SMARTICLES platform

Flexion Therapeutics' Zilretta NDA accepted for review by FDA

FDA awards fast track designation to Angionetics' Generx

Investigator-sponsored phase I trial of Actinium Pharmaceuticals' Actimab-M begins

Buparlisib shows promise in patients with platinum-pretreated recurrent head and neck carcinoma

Acticor Biotech raises funds to advance lead candidate

GeNeuro, NINDS enter agreement regarding antibodies for ALS

Series B financing at Prexton Therapeutics to support phase II trials of foliglurax

Cancer Research Technology, Tusk Therapeutics and UCL collaborate on cancer immunotherapies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...